There are currently 16 active clinical trials seeking participants for Crohn's Disease research studies. The states with the highest number of trials for Crohn's Disease participants are .
A Study to Evaluate the Efficacy and Safety of Tulisokibart (MK-7240) in Participants With Moderate to Severe Crohn's Disease (MK-7240-008)
Recruiting
The purpose of this protocol is to evaluate the efficacy and safety of tulisokibart in participants with moderately to severely active Crohn's disease. Study 1's primary hypotheses are that at least 1 tulisokibart dose level is superior to placebo in the proportion of participants achieving clinical remission per Crohn's Disease Activity Index score (\<150, US/FDA) or per stool frequency and abdominal pain score (EU/EMA) and in the proportion of participants achieving endoscopic response at Week... Read More
Gender:
ALL
Ages:
Between 16 years and 80 years
Trial Updated:
08/13/2025
Locations: Digestive Health Specialists ( Site 5064), Dothan, Alabama +421 locations
Conditions: Crohn's Disease
A Study to Investigate Efficacy and Safety of SAR441566 in Patients With Crohn's Disease.
Recruiting
This is a phase 2, multinational, multicenter, randomized, double-blind, placebo-controlled, dose-ranging study to evaluate the efficacy and safety of SAR441566 in adults with moderate to severe Crohn's Disease (CD). The primary objective of this study is to assess the efficacy of different doses of SAR441566 compared with placebo in participants with moderate to severe CD. This study will include a screening period of 4 weeks (+7 calendar days if needed), followed by the Main Study (MS) treatm... Read More
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
08/04/2025
Locations: GI Alliance - Sun City- Site Number : 8400020, Sun City, Arizona +99 locations
Conditions: Crohn's Disease
Study of Targeted Therapies for the Treatment of Adult Participants With Moderate to Severe Crohn's Disease
Recruiting
Crohn's disease (CD) is a long-lasting disease that causes severe inflammation (redness, swelling), in the digestive tract, most frequently affecting the bowels. It can cause many different symptoms including belly pain, diarrhea, tiredness, and weight loss. Treatments are available but do not work the same for all patients or may stop working over time. This study will evaluate the effectiveness and adverse events of targeted therapies (TaTs) for adult participants with moderate to severe CD.... Read More
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
07/30/2025
Locations: Digestive Health Specialists /ID# 266216, Dothan, Alabama +220 locations
Conditions: Crohn's Disease
A Phase 2 Study to Evaluate MORF-057 in Adults With Moderately to Severely Active Crohn's Disease
Recruiting
This is a Phase 2, randomized, double-blind, placebo-controlled, multicenter study to evaluate the efficacy and safety of 2 active dose regimens of MORF-057 in adult study participants with moderately to severely active Crohn's disease (CD).
Gender:
ALL
Ages:
Between 18 years and 85 years
Trial Updated:
07/29/2025
Locations: Gastro Care Institute, Lancaster, California +141 locations
Conditions: Inflammatory Bowel Diseases, Crohn's Disease
A Master Protocol (AMAZ): A Study of Mirikizumab (LY3074828) in Pediatric Participants With Ulcerative Colitis or Crohn's Disease (SHINE-ON)
Recruiting
The main purpose of this study is to evaluate the long-term efficacy of mirikizumab in pediatric participants with ulcerative colitis (UC) or Crohn's disease (CD). The study will last about 172 weeks and may include up to 44 visits. Additional treatment may be available to participants via a Continued Access Period.
Gender:
ALL
Ages:
Between 2 years and 19 years
Trial Updated:
07/22/2025
Locations: UCSF Medical Center at Mission Bay, San Francisco, California +60 locations
Conditions: Ulcerative Colitis, Ulcerative Colitis Chronic, Inflammatory Bowel Diseases, Crohn's Disease
Mirikizumab and Tirzepatide Administered in Adult Participants With Moderately to Severely Active Crohn's Disease and Obesity or Overweight
Recruiting
The main purpose of this study is to evaluate the efficacy and safety of mirikizumab and placebo compared with mirikizumab and concomitantly administered tirzepatide in adult participants with moderately to severely active CD and obesity, or overweight. The maximum duration of this study is up to 61 weeks.
Gender:
ALL
Ages:
Between 18 years and 70 years
Trial Updated:
07/22/2025
Locations: Digestive Health Specialists, Dothan, Alabama +188 locations
Conditions: Crohn's Disease, Obesity or Overweight
A Study of Guselkumab in Pediatric Participants With Moderately to Severely Active Crohn's Disease
Recruiting
The purpose of this study is to evaluate the clinical and endoscopic efficacy of guselkumab in pediatric participants with Crohn's Disease (CD) at the end of maintenance therapy (Week 52) among participants who were in clinical response to guselkumab at Week 12.
Gender:
ALL
Ages:
Between 2 years and 17 years
Trial Updated:
07/18/2025
Locations: Connecticut Children's Medical Center, Hartford, Connecticut +68 locations
Conditions: Crohn's Disease
Transmural Healing and Disease-Modifying Effect of Guselkumab in Crohn's Disease Patients
Recruiting
The purpose of this study is to evaluate the efficacy of guselkumab in healing of all layers of the digestive tract (transmural healing) with the help of a score called Magnetic Resonance Index of Activity (MaRIA) based on a scan at Week 48.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/17/2025
Locations: The Queen Elizabeth Hospital, Adelaide, Not set +66 locations
Conditions: Crohn's Disease
A Study of Vedolizumab Intravenous (IV) and Adalimumab or Vedolizumab and Ustekinumab in Adults With Crohn's Disease
Recruiting
The main aim of this study is to learn about the effect of treatment with vedolizumab IV (vedolizumab) together with adalimumab or vedolizumab (VDZ) together with ustekinumab (UST) in adults with moderate to severe Crohn's Disease, and the effect of treatment with vedolizumab alone, after the dual targeted treatment. The study is conducted in two parts. In Part A, participants will receive the dual targeted treatment (vedolizumab together with either adalimumab or ustekinumab). In part B, parti... Read More
Gender:
ALL
Ages:
Between 18 years and 70 years
Trial Updated:
07/10/2025
Locations: Digestive Health Specialsits, Dothan, Alabama +52 locations
Conditions: Crohn's Disease
A Study of Mirikizumab (LY3074828) in Pediatric Participants With Crohn's Disease
Recruiting
Study participants will be screened during the platform study and randomly assigned to receive mirikizumab or another intervention. The purpose of the mirikizumab study is to evaluate efficacy, safety, tolerability, and how well mirikizumab absorbs into the body of pediatric participants with Crohn's disease. Study periods for the intervention-specific appendix (ISA) will be as follows: * A 12-week induction period * A maintenance period from Week 12 to Week 52, and * A safety follow-up period... Read More
Gender:
ALL
Ages:
Between 2 years and 17 years
Trial Updated:
07/07/2025
Locations: University of California San Diego, La Jolla, California +82 locations
Conditions: Crohn's Disease
A Study to Assess Adverse Events, Change in Disease Activity, and How Intravenous and Subcutaneous Risankizumab Moves Through the Body of Pediatric Participants With Moderately to Severely Active Crohn's Disease
Recruiting
Crohn's Disease (CD) is a gastrointestinal disease that can cause chronic diarrhea with or without gross bleeding, abdominal pain, weight loss, and fever. This study will assess the pharmacokinetics, efficacy, and safety of risankizumab in pediatric participants with moderately to severely active CD aged 2 to \< 18 years old who have had intolerance or inadequate response to other therapies. Risankizumab is an approved drug for adults with plaque psoriasis, psoriatic arthritis, and CD and is be... Read More
Gender:
ALL
Ages:
Between 2 years and 17 years
Trial Updated:
06/13/2025
Locations: Phoenix Children's Hospital /ID# 255766, Phoenix, Arizona +82 locations
Conditions: Crohn's Disease
A Study of Vedolizumab With and Without Upadacitinib in Adults With Crohn's Disease
Recruiting
The main aim of this study is to learn whether vedolizumab and upadacitinib given together (also called dual targeted therapy or DTT) reduces bowel inflammation and ulcers in the bowel compared to vedolizumab only (also called monotherapy) in adults with moderately or severely active Crohn's Disease (CD) after 12 weeks of treatment. Other aims are to learn how safe and effective DTT is compared to monotherapy for these participants. All participants will receive DTT (either vedolizumab and upad... Read More
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
05/28/2025
Locations: UCSD Medical Center, La Jolla, California +137 locations
Conditions: Crohn's Disease